TriangleTivozanib (NCT06053658)
Tivozanib trial for Renal Cell Carcinoma (NCT06053658). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic non-clear-cell kidney cancers and no more than one previous systemic treatment line. Medullary and collecting-duct cancers are excluded, as is prior tivozanib or nivolumab.
The idea: combine tivozanib, which blocks blood-vessel growth receptors, with nivolumab, which blocks PD-1 to support immune attacks on cancer. Patients take tivozanib daily for three weeks, then pause for one week; nivolumab is infused every four weeks. Researchers assess safety, tumor control and how long it lasts.
This phase 2 study plans 48 patients. Eric Jonasch leads six recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.